Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: role of tumour necrosis factor alpha

L Santucci, S Fiorucci, M Giansanti, P M Brunori, F M Di Matteo, A Morelli

Abstract

Neutrophil adherence within the gastric microcirculation is thought to be a major step in the pathogenesis of gastric mucosal damage induced by indomethacin. Pentoxifylline, a methylxanthine derivative, prevents leukocyte adherence to vascular endothelium and protects organs from shock by reducing tumour necrosis factor α (TNF α) concentrations. Rats were treated with 20 mg/kg oral indomethacin, pretreated with vehicle or with four different doses of pentoxifylline intraperitoneally, and killed after three hours. The gross gastric mucosal injury, neutrophil margination into the gastric microcirculation, mucosal concentrations of 6-keto-prostaglandin F_{1 α} (PGF_{1 α}), and PGE₂ and serum TNF α values were measured. Whether the pentoxifylline induced protection involved nitric oxide mediated pathways or gastric acid secretion was evaluated. The data indicate that pentoxifylline reduces indomethacin induced mucosal damage and neutrophil margination in a dose dependent manner without exerting any effect on gastric mucosal prostaglandin concentrations. The maximally effective dose (200 mg/kg) of pentoxifylline reduced gastric damage by 90% and slightly stimulated acid secretion. The effect of pentoxifylline was not affected by pretreatment with the nitric oxide inhibitor. Pentoxifylline prevented the indomethacin induced increase in TNF α concentrations in a dose dependent fashion. Serum TNF α values were 30.5 (7.0) IU/ml (mean SEM)) in rats treated with indomethacin alone and 5.0 (2.5) IU/ml ($p < 0.01$) in rats treated with indomethacin plus 200 mg/kg pentoxifylline. Pentoxifylline, therefore, prevents the acute gastric mucosal damage and neutrophil margination induced by indomethacin and reduces indomethacin induced release of TNF α .

(Gut 1994; 35: 909-915)

Ulcerative lesions of the gastrointestinal tract are one of the major side effects associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs).¹ Although the mechanism of NSAID induced gastric injury is unclear, evidence is accumulating that neutrophils (PMNs) play a crucial role.²⁻⁵ Depletion of circulating PMNs by antineutrophil serum or methotrexate prevents NSAID induced gastric

damage in rats, without interfering with prostaglandin metabolism.^{3,4} Moreover, it has been shown that prevention of PMN adherence to the endothelium by treatment with a serum specifically directed against the PMN adhesion complex (CD18) reduces the gastrointestinal injury induced by indomethacin and ischaemia-reperfusion.^{5,6}

Pentoxifylline (PTX) is a methylxanthine derivative that exerts a number of haemorrhological, haemodynamic, and anti-inflammatory effects. PTX has recently been shown to reduce effectively PMN adherence in vitro in septic shock and ischaemia-reperfusion models.⁷ Furthermore, PTX inhibits synthesis and release of the tumour necrosis factor α (TNF α) by macrophages.⁸⁻¹⁰ TNF α is a cytokine that is known to stimulate considerably the adherence of PMN to the vascular endothelium by inducing the expression of β_2 integrins (LFA-1 and MAC-1).¹¹⁻¹³ Administration of TNF α to rats leads to vasocongestion, leukocyte margination, and tissue damage, and this effect is particularly evident in the gastrointestinal tract.¹³⁻¹⁶ Furthermore, it has been shown that, both in vitro and in vivo, NSAIDs increase TNF α concentrations by inhibiting PGE₂ synthesis.¹⁷⁻²⁰ However, the part TNF α plays in the pathogenesis of NSAID induced gastrointestinal damage is unknown.

The present study evaluated whether: (1) PTX reduces gastric mucosal damage induced by indomethacin; (2) PTX administration modulates gastric acid secretion, serum TNF α values, and PMN infiltration into the gastric microcirculation; and (3) a functioning prostaglandin or nitric oxide (NO) system, or both, is required for PTX to protect the gastric mucosa against indomethacin induced gastric injury.

Methods

ASSESSMENT OF GASTRIC DAMAGE

Male Wistar rats (200-250 g), obtained from Charles River, Italia (Como, Italy), were fasted for 20-22 hours and deprived of water two to four hours before each experiment. Gastric mucosal damage was induced by the intragastric instillation of 20 mg/kg indomethacin (Sigma, St Louis, MO, USA) dissolved in 5% sodium bicarbonate. This dose of indomethacin has been found to elicit macroscopically visible haemorrhagic erosions and ulcers in the stomach of normal rats.³ The control group received only the vehicle (5%

Clinica di
Gastroenterologia ed
Endoscopia Digestiva
and Istituto di
Anatomia Patologica,
Università degli Studi
di Perugia
L Santucci
S Fiorucci
M Giansanti
P M Brunori
F M Di Matteo
A Morelli

Correspondence to:
Dr A Morelli, Clinica di
Gastroenterologia,
Policlinico Monteluce,
06122, Perugia, Italy.

Accepted for publication
10 November 1993

sodium bicarbonate). Gastric damage was assessed three hours after administration of indomethacin. The rats were killed and the stomachs rapidly removed, opened by an incision along the greater curvature, pinned out on a wax platform, and photographed. The lesions, haemorrhagic or ulcerative, were counted and measured with microcalipers by an observer who was unaware of the treatment.³ The gastric damage score was then calculated as the sum of the lengths of all lesions. Samples (3×10 mm) of the corpus were excised and transferred to fresh formalin for histological studies and later processed by routine techniques before embedding in paraffin. Sections 4 µm thick were mounted on glass slides and stained with haematoxylin and eosin. Coded slides were examined by an experienced pathologist unaware of the treatment. The extent of leukocyte margination in the sections was scored on a 0–3 scale,³ where 0 indicated none; 1 limited to superficial (sub-epithelial) vessels; 2 extending to the bottom of the gastric glands; 3 extending to the vessels immediately above the muscularis mucosae or submucosa, or both.

PROSTAGLANDIN MEASUREMENT

In the same set of experiments, samples of the body region of the stomach, including the whole gastric wall, were excised for determining 6-keto-prostaglandin $F_{1\alpha}$ (6-keto-PGF $_{1\alpha}$) and prostaglandin E_2 (PGE $_2$) concentrations.²¹ Briefly, the tissue samples were weighed and then homogenised on ice in 4.3 ml of Tris buffer plus 1 mM EDTA (pH 8.9 at 5°C) using a ground glass homogeniser. The homogenates were centrifuged at 2000 *g* for 10 minutes to remove the tiny amounts of solid tissue debris. The resultant supernatant was then acidified with acetic acid. Prostaglandins were extracted from the supernatant using columns packed with reverse-phase octadecylsilane bonded silica gel (Sep-Pac C18, Waters, Millipore Co, Milford, MT). Columns were conditioned before use by washing them with 5 ml of ethanol, followed by 5 ml water. The acidified supernatants were added to the column that was then washed sequentially with 5 ml of 15% ethanol and 5 ml of toluene. Prostaglandins were eluted with 2 ml of ethyl acetate, the solvent evaporated under a stream of nitrogen gas and the prostaglandins assayed using a specific enzyme immunoassay (Cayman Chemical Co, Ann Arbor, MI). The lower detection limit of the prostaglandin assay was 7 pg/ml, with a sensitivity of 90% and a specificity of 100%.^{22, 23} Results are expressed as pg/mg of wet tissue.

EFFECT OF PTX ON BASAL GASTRIC ACID SECRETION

To evaluate the effect PTX exerts on basal gastric acid secretion, three groups of five rats each were pretreated with vehicle, 200 mg/kg intraperitoneal PTX, or 15 mg/kg intraperitoneal ranitidine. One hour later, rats were killed by an overdose of ether, and laparotomy

was performed. The stomach was clamped at the junctions with the oesophagus and duodenum and excised. The gastric contents were emptied into a glass tube, centrifuged at 1000 rpm, the volume measured, and the amount of titrable acidity determined by titrating the samples at pH 7.0 with 0.01 mol/l NaOH using an automatic titration system (Radiometer, Copenhagen, Denmark).

COLORIMETRIC ASSAYS FOR DETECTION OF TNF α IN RAT SERUM

The chests of rats were opened and blood was drawn directly from the heart under anaesthesia. The biologically active TNF α was determined by a previously described cytotoxicity assay.²⁴ Briefly, mouse fibrosarcoma L929 cells, which are highly sensitive to TNF α , were used as target cells. Cells (4×10^5) were cultured in 96-well microtitre plates at 37°C in 100 µl RPMI 1640 medium (Sigma, Milano, Italy) containing 10% fetal calf serum and 1 µg/ml actinomycin D (Boehringer Manneheim Biochemicals, Milano, Italy). Samples of rat serum (100 µl) were added to the wells and incubated with the L929 cells for 24 hours at 37°C. Cytopathic effects induced by TNF α were assessed by staining fibrosarcoma cells with a 0.1% solution of crystal violet suspension in 5% ethanol. One unit of TNF α was defined as the concentration at which 50% of the L929 cells manifested cytopathic effects. Purified recombinant human TNF α (Boehringer Manneheim Biochemicals, Milano, Italy) was included as standard in each assay. A dose/response curve of TNF α release was determined on the same rats as in Figure 1 after intraperitoneal administration of PTX at doses of 200, 100, 50, and 20 mg/kg (Fig 7) 30 minutes before indomethacin.

EFFECT OF PTX ON INDOMETHACIN INDUCED GASTRIC DAMAGE

A dose/response curve of the effect that PTX (Trental, Hoechst, Milano, Italy) exerted on indomethacin induced gastric mucosal damage was constructed using five groups of rats treated as follows: group A, 20 mg/kg oral indomethacin alone; group B, 200 mg/kg intraperitoneal PTX given 30 minutes before the indomethacin; group C, 100 mg/kg intraperitoneal PTX given 30 minutes before indomethacin; group D, 50 mg/kg intraperitoneal PTX given 30 minutes before indomethacin; and group E, 20 mg/kg intraperitoneal PTX given 30 minutes before indomethacin.

EFFECT OF PRETREATMENT WITH INHIBITOR OF NO BIOSYNTHESIS ON PTX INDUCED PROTECTION

In a separate set of experiments, five groups of rats were assigned to receive one of the following treatments: group A, 20 mg/kg oral indomethacin; group B, 40 mg/kg of N ω -nitro-L-arginine (L-NNA)²⁵ (Sigma, Milano, Italy)

Figure 1: Effect of pentoxifylline (PTX) administration on the gastric mucosal damage score induced by intragastric instillation of 20 mg/kg indomethacin or vehicle (5% sodium bicarbonate). Each group consisted of five to 10 rats. * $p < 0.01$ v vehicle; ** $p < 0.01$ v indomethacin group (ANOVA and Student-Newman-Keul's test).

given intraperitoneally 30 minutes before vehicle; group C, 40 mg/kg L-NNA given intraperitoneally 30 minutes before 20 mg/kg indomethacin; group D, 40 mg/kg L-NNA and 200 mg/kg PTX given intraperitoneally 30 minutes before 20 mg/kg indomethacin; and group E, 200 mg/kg intraperitoneal PTX given 30 minutes before 20 mg/kg indomethacin.

STATISTICAL ANALYSIS

All data are expressed as mean (SEM). Differences between groups were compared using an analysis of variance (ANOVA) followed by a Student-Newman-Keul's test. A probability (p value) of $< 5\%$ was considered significant.

Results

GASTRIC DAMAGE

Luminal administration of the vehicle produced negligible damage in the rat stomach, while indomethacin caused haemorrhagic and ulcerative lesions (Fig 1). The ulcerations were linear, with a mean length of 6–7 mm, and were frequently located along the rugal folds, while the antrum was largely spared. The mean gastric mucosal damage score was 52.4 (11.0) mm in indomethacin treated rats. PTX administration reduced indomethacin induced gastric damage in a dose dependent fashion. The maximum dose of PTX (200 mg/kg) reduced the extent of indomethacin induced damage by 90% (5.0 (1.2) mm; $p < 0.01$) (Fig 1). PTX alone caused slight oedema and hyperaemia of gastric mucosa. When the percentage reduction of gastric damage induced by 20 mg/kg

indomethacin was plotted against the PTX concentrations tested, a linear correlation was found (Fig 2). The 50% inhibitory dose (ID_{50}) was 50 mg/kg.

PMN MARGINATION INTO GASTRIC MUCOSA

Indomethacin resulted in extensive vascular engorgement of the mucosal and submucosal vessels. The results of the histological evaluation of PMN margination into the gastric microcirculation are shown in Figure 3. Indomethacin induced a significant increase in PMN margination. PTX, in doses of 200 and 100 mg/kg, significantly reduced the margination score ($p < 0.05$ v indomethacin alone). As shown previously for the gastric damage score,

Figure 2: Correlation between the percentage reduction in gastric mucosal damage and pentoxifylline (PTX) doses. (Data were obtained from Figure 1.)

Figure 3: Effect of pentoxifylline (PTX) administration on the histological score of leukocyte margination induced by intragastric instillation of 20 mg/kg indomethacin or vehicle (5% sodium bicarbonate). Each group consisted of five to 10 rats. * $p < 0.05$ v vehicle; ** $p < 0.05$ v indomethacin alone group. (See Methods for details of the criteria used for scoring.)

Figure 4: Correlation between the percentage reduction in the polymorphonuclear (PMN) infiltration score and pentoxifylline (PTX) doses. (Data were obtained from Figure 3.)

Figure 5: Gastric mucosal concentrations of prostaglandins in untreated rats (vehicle group), in rats treated with 20 mg/kg indomethacin alone or in rats pretreated with pentoxifylline (PTX). Each group consisted of five to 10 rats. **p*<0.01 *v* vehicle group.

PTX caused a dose dependent reduction in the PMN margination score, and the ID₅₀ was 100 mg/kg (Fig 4).

EFFECT OF INDOMETHACIN AND PTX ON GASTRIC MUCOSAL PROSTAGLANDIN CONCENTRATIONS
The mean concentrations of PGE₂ and 6-keto-PGF_{1α} were 70.2 (12.5) pg/mg and 324.0

Figure 6: Effect of administration of vehicle, 15 mg/kg ranitidine, and 200 mg/kg pentoxifylline (PTX) on basal gastric acid secretion. Rats were pretreated with the reported agents and killed one hour later. Each group consisted of five rats. **p*<0.05 *v* vehicle.

(21.2) pg/mg respectively in control rats and 3.3 (0.1) pg/mg and 33.6 (15.1) pg/mg respectively in indomethacin treated animals (>90% reduction; *p*<0.01). PTX administration did not interfere with the reduction of gastric prostanoids induced by indomethacin (*p*>0.05 *v* indomethacin alone) (Fig 5).

EFFECT OF PTX ON GASTRIC ACID SECRETION
PTX caused a 10 fold increase in gastric volume content, from 90.0 (19.6) to 900.0 (276.9) μl (*p*<0.05) (Fig 6, upper panel), and a fourfold increase in titrable acidity from 5.2 (1.7) to 20.6 (9.3) (*p*<0.05) (Fig 6, lower panel). Ranitidine administration reduced the titrable acidity by approximately 90%, but had no effect on the gastric juice volume.

EFFECT OF INDOMETHACIN AND PTX ON SERUM TNFα CONCENTRATIONS
The mean (SEM) TNFα concentrations were 7.6 (2.0) IU/ml in control rats. Indomethacin significantly increased TNFα concentrations (Fig 7), while PTX inhibited TNFα release in a dose dependent fashion. When serum TNFα concentrations were plotted against the gastric mucosal damage or PMN margination score, a

linear correlation was found (Fig 8, upper and lower panel). The ID₅₀ of PTX inhibition on indomethacin induced TNF α release was approximately 100 mg/kg.

EFFECT OF PRETREATMENT WITH NO INHIBITOR ON PTX INDUCED GASTRIC PROTECTION

Pretreatment with 40 mg/kg L-NNA increased the indomethacin induced gastric damage from 48.0 (8.0) mm to 68.0 (10.0) mm, but this difference was not significant. Pretreatment with L-NNA did not, however, reverse the protective effect 200 mg/kg PTX provided against indomethacin induced gastric damage (48.0 (8.0) mm *v* 6.2 (0.5) mm, *p*<0.05) (Fig 9).

Discussion

The results of the present study show that PTX prevents the acute gastric damage induced by indomethacin. This drug, a methylxanthine derivative, is a haemorrhological agent used for the treatment of peripheral and cerebrovascular diseases. It mainly acts by improving erythrocyte deformability and reducing blood viscosity, platelet aggregation, and plasma fibrinogen concentrations. Recent studies have indicated that PTX has anti-inflammatory properties. It inhibits PMN activation^{26,27} and interleukin 2 (IL-2) mediated PMN adhesion to the vascular endothelium²⁸ and reduces the synthesis and release of IL-2, IL-6, and TNF α both in vitro and in vivo.⁸⁻¹⁰

The protective effect of PTX shown in this investigation was dose dependent with an ID₅₀ of approximately 50 mg/kg. PTX was very effective in reducing indomethacin induced

gastric damage and the highest dose tested caused an approximately 90% reduction in gastric mucosal injury. Several mechanisms could be proposed to account for the protective effect of PTX. Our data indicate that this effect is unrelated to gastric mucosal prostaglandin generation, since pretreatment with doses of PTX which reduced gastric damage by 90% had no effect on the gastric mucosal prostaglandin concentrations. Furthermore, PTX significantly increased the volume of basal gastric juice and titrable acidity, indicating that its protective effect is not related to the inhibition of gastric acid secretion, as has been shown for other protective agents, such as IL-1 or antisecretory drugs.²⁹ The fact that the gastric juice volume was increased approximately 10 fold, while titrable acidity was increased only fourfold, however, suggests that PTX increases the non-oxintic secretion rather than parietal cell secretion. The non-oxintic secretion is a mixture of interstitial fluid (paracellular diffusion) and mucous cell secretion.³⁰ Since PTX has previously been shown to increase intestinal microvascular blood flow,³¹ it may be hypothesised that PTX increases paracellular diffusion of interstitial fluid by enhancing

Figure 7: Effect of administration of 20 mg/kg indomethacin alone or plus 200 mg/kg pentoxifylline (PTX) on serum tumour necrosis factor α (TNF α) concentrations. Each group consisted of five to 10 rats. **p*<0.05 *v* vehicle group; ***p*<0.01 *v* indomethacin alone group.

Figure 8: Correlation between serum tumour necrosis factor α (TNF α) concentrations and gastric mucosal damage score (upper panel) and polymorphonuclear (PMN) margination score (lower panel).

Figure 9: Effect of administration of 40 mg/kg Nω-nitro-L-arginine (L-NNA) on the gastric mucosal damage score induced by intragastric instillation of 20 mg/kg indomethacin alone or plus 200 mg/kg pentoxifylline (PTX). Each group consisted of five rats. **p*<0.05 v vehicle. ***p*<0.05 v indomethacin alone or indomethacin plus L-NNA.

gastric mucosal blood flow. Since indomethacin reduced the gastric mucosal prostaglandin concentration to the same extent in rats pretreated with PTX or vehicle, it is unlikely that this increment in the gastric volume had any effect on indomethacin pharmacokinetics.

The indomethacin induced PMN margination into the microcirculation of the gastric mucosa documented in our study is consistent with the hypothesis that PMN are important mediators of NSAID induced acute mucosal injury.²⁻⁵ Kitahora and Guth² reported that the development of vascular stasis and mucosal lesions induced by indomethacin is immediately preceded by the appearance of white thrombi in the gastric microcirculation, and it has been shown that NSAID provoked gastric damage can be prevented by inducing neutropenia with methotrexate or antineutrophil monoclonal antibodies.^{3,4} As our results shown that PTX administration dose-dependently inhibited PMN infiltration into the gastric mucosa, they offer further confirmation that PMN margination plays an important role in the pathogenesis of indomethacin induced gastric mucosal damage. A similar picture has recently been reported for IL-1, which has been found to reduce the severity of experimental NSAID induced gastric damage by inhibiting the extent of PMN margination.²⁹ In addition, as PTX has been shown to reduce elastase and superoxide anion release from PMN *in vitro*,^{26,27} it may block the activation and release of toxic substances by PMN margined into the gastric microcirculation.

PTX could inhibit PMN adherence in a number of ways. PMN adherence is dependent on the appearance of specific surface adhesion

proteins on the cell membrane and several agents (for example, leukotriens, IL-1, IL-2, and TNFα) are able to induce these adhesion molecules. TNFα is a cytokine that strongly stimulates PMN adherence by inducing the synthesis and expression of the intercellular adhesion molecules ICAM-1 and ELAM-1 on endothelial cells¹¹ and LFA-1 and MAC-1 on PMN.³² Intravenous administration of TNFα produces extensive PMN margination within the microvasculature of the digestive tract, as well as a spotty necrosis on the surface epithelium of the small bowel and colon.¹⁴ Furthermore, studies on experimental models of septic shock have shown that TNFα is responsible for the PMN margination and the resulting organ injury.¹³ *In vitro* studies have documented that indomethacin increases TNFα synthesis from lipopolysaccharide (LPS) stimulated macrophages, whereas exogenous PGE₂ suppresses the release of TNFα, as well as the expression of the TNF gene in a dose dependent fashion,¹⁷⁻²⁰ indicating that cyclo-oxygenase products may serve as part of the inhibitory feedback loop that limits monocyte-macrophage TNFα production. It has also been shown that NSAID administration increases TNFα concentrations in both humans and experimental animals.^{19,33} The present results show that PTX administration reduces dose dependently the indomethacin induced TNFα increase. There was also a linear correlation between serum TNFα concentrations and both gastric mucosal damage and PMN margination scores, suggesting that prevention of gastric injury and PMN margination by PTX may depend, at least partly, on its ability to modulate TNFα release.

PTX has been shown to increase gastrointestinal blood flow in animal models of haemorrhagic shock.³¹ In these models, PTX leads to an immediate hyperaemic response, with an increase in microvascular blood flow that protects tissues from the ischaemic damage. This hyperaemic response is mainly dependent on its ability to both increase erythrocyte deformability and reduce blood viscosity, platelet aggregation, and PMN margination.³¹ These haemorreological effects may also contribute to the ability of PTX to prevent indomethacin induced gastric mucosal damage. Although NO has been shown to be a potent vasodilator in the gastrointestinal tract, the fact that L-NNA, a specific inhibitor of NO generation, did not eliminate the protective effect of PTX, suggests that these actions are not mediated by local release of NO.²⁵

PTX could also reduce PMN adherence by increasing the local release of factors that inhibit PMN margination. One of these is prostacyclin,³⁴ the major prostaglandin produced by the endothelium. This seems unlikely, however, since we showed that PTX reduces PMN margination within the microcirculation without exerting any effect on the mucosal concentrations of 6-keto-PGF_{1α}, the stable metabolite of prostacyclin.

In conclusion, PTX prevents indomethacin induced gastric damage in rats. The effect of

PTX is not related to the synthesis of prostaglandins or to the inhibition of acid secretion, but rather seems, at least partly, to depend on blocking the adherence of PMN to the gastric microcirculation, probably by inhibiting TNF α synthesis and release.

We thank Judy Dale for reviewing the manuscript and Barbara Federici, Francesca Orsini, and Guido Giglietti for technical assistance.

- Ivey KJ. Mechanism of NSAID-induced gastric damage: actions of therapeutic agents. *Am J Med* 1988; **84** (suppl 2A): 41-8.
- Kitahora T, Guth PH. Effect of aspirin plus hydrochloric acid on the gastric mucosal microcirculation. *Gastroenterology* 1987; **93**: 810-7.
- Wallace JL, Keenan CM, Granger DN. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. *Am J Physiol* 1990; **259**: G462-7.
- Lee M, Feldman M. Aspirin-induced acute gastric mucosal injury is a neutrophil-dependent process in rats. *Am J Physiol* 1992; **26**: G920-6.
- Wallace JL, Arfors KE, McKnight GW. A monoclonal antibody against the CD18 leukocyte adhesion molecule prevents indomethacin-induced gastric damage in the rabbit. *Gastroenterology* 1991; **100**: 878-83.
- Vedder NB, Winn RK, Rice CL, Chi EY, Arfors KE, Harlan JM. A monoclonal antibody to the adherence-promoting leukocyte glycoprotein, CD18, reduces organ injury and improves survival from hemorrhagic shock and resuscitation in rabbits. *J Clin Invest* 1988; **81**: 939-44.
- Yonemaru M, Hatherill JR, Hoffmann H, Zheng H, Ishii K, Raffin TA. Pentoxifylline does not attenuate acute lung injury in the absence of granulocytes. *J Appl Physiol* 1991; **71**: 342-51.
- Doherty GM, Jensen JC, Alexander HR, Buresh CM, Norton JA. Pentoxifylline suppression of tumor necrosis factor gene transcription. *Surgery* 1991; **110**: 192-8.
- LeMay LG, Vander AJ, Kluger MJ. The effects of pentoxifylline on lipopolysaccharide (LPS) fever, plasma interleukin 6 (IL6), and tumor necrosis factor (TNF) in the rat. *Cytokine* 1990; **2**: 300-6.
- Zabel P, Schonharting MM, Shade UF, Schlaak JM. Effect of pentoxifylline in endotoxemia in human volunteers. *Prog Clin Biol Res* 1991; **367**: 207-13.
- Pohlman TH, Stannes KA, Beatty PG, Ochs HD, Harlan JM. An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1 and tumor necrosis factor- α increases neutrophil adherence by CDw18-dependent mechanism. *J Immunol* 1986; **136**: 4548-53.
- Birdsall HH. Induction of ICAM-1 on human neural cells and mechanisms of neutrophil-mediated injury. *Am J Pathol* 1991; **139**: 1341-50.
- Tracey KJ, Beutler B, Lowrey SL, Merryweather J, Wolpe S, Milsark IW, et al. Shock and tissue injury induced by recombinant human cachectin. *Science* 1986; **234**: 470-5.
- Remick DG, Kunkel RG, Larrick JW, Kunkel SL. Acute in vivo effects of human recombinant tumor necrosis factor. *Lab Invest* 1987; **56**: 583-90.
- Sayers TG, Wiltout TA, Bull CA, Denn III AC, Piloro AM, Lokesh B. Effect of cytokines on polymorphonuclear neutrophil infiltration in the mouse. *J Immunol* 1988; **141**: 1670-7.
- Kettelhut IC, Fiers W, Goldberg LA. The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. *Proc Natl Acad Sci USA* 1987; **84**: 4273-7.
- Fieren MW, Van den Bermd GJ, Ben-Efraim S, Bonta IL. Prostaglandin E2 inhibits the release of tumor necrosis factor- α , rather than interleukin 1 β , from human macrophages. *Immunol Lett* 1992; **31**: 85-90.
- Marcinkiewicz J. In vitro cytokine release by activated murine peritoneal macrophages: role of prostaglandins in the differential regulation of tumor necrosis factor α , interleukin 1, and interleukin 6. *Cytokine* 1991; **3**: 327-32.
- Spatafora M, Chiappara G, D'Amico D, Volpes D, Melis M, Pace E, Merendino A. Effect of indomethacin on the kinetics of tumor necrosis factor- α release and tumor necrosis factor α gene expression by human blood monocytes. *Pharmacol Res* 1991; **23**: 247-57.
- Ferri NR, Sarr T, Askenase PW, Ruddle NH. Molecular regulation of tumor necrosis factor- α and lymphotoxin production in T cells. Inhibition by prostaglandin E $_2$. *J Biol Chem* 1992; **267**: 9443-9.
- Redfern JS, Lee E, Feldman M. Effect of indomethacin on gastric mucosal prostaglandins in human. Correlation with mucosal damage. *Gastroenterology* 1987; **92**: 969-77.
- Ferman N, Pradelles P, Bonvalet JP. PGE $_2$, PGF $_{2\alpha}$, 6-keto-PGF $_{1\alpha}$ and TXB $_2$ synthesis along the rabbit nephron. *Am J Physiol* 1987; **252**: F53-9.
- Pradelles P, Grassi J, Maclof J. Enzyme immunoassays of eicosanoids using acetylcholine esterase as label: an alternative to radioimmunoassay. *Anal Chem* 1985; **57**: 1170-3.
- Lau AS, Livesey JS. Endotoxin induction of tumor necrosis factor is enhanced by acid-labile interferon- α in acquired immunodeficiency syndrome. *J Clin Invest* 1989; **84**: 738-43.
- Whittle BJR, Lopez-Belmonte J, Moncada S. Regulation of gastric mucosal integrity by endogenous nitric oxide: interactions with prostanoids and sensory neuropeptides in rat. *Br J Pharmacol* 1990; **99**: 607-11.
- Oka Y, Murata A, Nishijima J, Hiraoka N, Yasuda T, Kitagawa K, et al. Inhibitory effect of pentoxifylline and prostaglandin E1 on the release of neutrophil elastase from FMLP-stimulated neutrophils. *J Med Clin Exp Ther* 1991; **22**: 371-82.
- Thiel M, Bordenheuer H, Poch G, Madel C, Peter K. Pentoxifylline does not act via adenosine receptors in the inhibition of the superoxide anion production of human polymorphonuclear leukocyte. *Biochem Biophys Res Commun* 1991; **180**: 53-8.
- Edwards MJ, Abney DL, Miller FN. Pentoxifylline inhibits interleukin-2-induced leukocyte-endothelial adherence and reduces systemic toxicity. *Surgery* 1991; **110**: 199-204.
- Wallace JL, Keenan CM, Cucala M, Mugridge KG, Parente L. Mechanisms underlying the protective effects of interleukin 1 in experimental nonsteroidal anti-inflammatory drug gastropathy. *Gastroenterology* 1992; **102**: 1176-85.
- Daugherty DF, Lucey MR, Yamada T. Gastric secretion. In: Yamada T, ed. *Textbook of gastroenterology*. Philadelphia: JB Lippincott Co, 1991: 233-64.
- Flynn WJ, Cryer HG, Garrison RN. Pentoxifylline restores intestinal microvascular blood flow during resuscitated hemorrhagic shock. *Surgery* 1991; **110**: 350-6.
- Dustin ML, Springer TA. T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. *Nature* 1989; **341**: 619-24.
- Martich GD, Parker MM, Cunnion RE, Suffredini AF. Effect of ibuprofen and pentoxifylline on the cardiovascular response of normal humans to endotoxin. *J Appl Physiol* 1992; **73**: 925-31.
- Fantone JC. Mechanism of chemotactic factor stimulation of polymorphonuclear leukocyte: modulation by prostaglandins. In: Higgs GA, Williams TJ, eds. *Inflammatory mediators*. London: MacMillan, 1985: 127-48.